CRISPRoff-v2.1 Citations (4)
Originally described in: Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.Nunez JK, Chen J, Pommier GC, Cogan JZ, Replogle JM, Adriaens C, Ramadoss GN, Shi Q, Hung KL, Samelson AJ, Pogson AN, Kim JYS, Chung A, Leonetti MD, Chang HY, Kampmann M, Bernstein BE, Hovestadt V, Gilbert LA, Weissman JS Cell. 2021 Apr 7. pii: S0092-8674(21)00353-6. doi: 10.1016/j.cell.2021.03.025. PubMed Journal
Articles Citing CRISPRoff-v2.1
Articles |
---|
Determinants of heritable gene silencing for KRAB-dCas9 + DNMT3 and Ezh2-dCas9 + DNMT3 hit-and-run epigenome editing. O'Geen H, Tomkova M, Combs JA, Tilley EK, Segal DJ. Nucleic Acids Res. 2022 Apr 8;50(6):3239-3253. doi: 10.1093/nar/gkac123. PubMed |
Nuclear receptor ligand screening in an iPSC-derived in vitro blood-brain barrier model identifies new contributors to leptin transport. Shi Y, Kim H, Hamann CA, Rhea EM, Brunger JM, Lippmann ES. Fluids Barriers CNS. 2022 Sep 21;19(1):77. doi: 10.1186/s12987-022-00375-3. PubMed |
Functional Validation of the Putative Oncogenic Activity of PLAU. Sarno F, Goubert D, Logie E, Rutten MGS, Koncz M, Deben C, Niemarkt AE, Altucci L, Verschure PJ, Kiss A, Berghe WV, Rots MG. Biomedicines. 2022 Dec 30;11(1):102. doi: 10.3390/biomedicines11010102. PubMed |
Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma. Han X, Abdallah MOE, Breuer P, Stahl F, Bakhit Y, Potthoff AL, Pregler BEF, Schneider M, Waha A, Wullner U, Evert BO. Neoplasia. 2023 Oct;44:100929. doi: 10.1016/j.neo.2023.100929. Epub 2023 Aug 25. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.